Malcolm Fisher Department of Intensive Care, Royal North Shore Hospital, St Leonards, NSW, Australia.
The Kirby Institute, The University of New South Wales, Kensington, NSW, Australia.
Front Immunol. 2023 Jan 11;13:1077414. doi: 10.3389/fimmu.2022.1077414. eCollection 2022.
Acute pancreatitis (AP) is characterised by an inflammatory response that in its most severe form can cause a systemic dysregulated immune response and progression to acute multi-organ dysfunction. The pathobiology of the disease is unclear and as a result no targeted, disease-modifying therapies exist. We performed a scoping review of data pertaining to the human immunology of AP to summarise the current field and to identify future research opportunities.
A scoping review of all clinical studies of AP immunology was performed across multiple databases. Studies were included if they were human studies of AP with an immunological outcome or intervention.
205 studies met the inclusion criteria for the review. Severe AP is characterised by significant immune dysregulation compared to the milder form of the disease. Broadly, this immune dysfunction was categorised into: innate immune responses (including profound release of damage-associated molecular patterns and heightened activity of pattern recognition receptors), cytokine profile dysregulation (particularly IL-1, 6, 10 and TNF-α), lymphocyte abnormalities, paradoxical immunosuppression (including HLA-DR suppression and increased co-inhibitory molecule expression), and failure of the intestinal barrier function. Studies including interventions were also included. Several limitations in the existing literature have been identified; consolidation and consistency across studies is required if progress is to be made in our understanding of this disease.
AP, particularly the more severe spectrum of the disease, is characterised by a multifaceted immune response that drives tissue injury and contributes to the associated morbidity and mortality. Significant work is required to develop our understanding of the immunopathology of this disease if disease-modifying therapies are to be established.
急性胰腺炎(AP)的特征是炎症反应,在其最严重的形式中,可导致全身失调的免疫反应,并进展为急性多器官功能障碍。该疾病的病理生物学尚不清楚,因此不存在针对该疾病的靶向治疗方法。我们对与 AP 人类免疫学相关的数据进行了范围界定审查,以总结当前领域并确定未来的研究机会。
在多个数据库中对 AP 免疫学的所有临床研究进行了范围界定审查。如果研究是针对 AP 且具有免疫学结果或干预措施的人类研究,则将其纳入研究范围。
有 205 项研究符合本综述的纳入标准。与疾病的较轻形式相比,严重 AP 的特征是明显的免疫失调。广义上,这种免疫功能障碍可分为:固有免疫反应(包括损伤相关分子模式的大量释放和模式识别受体的活性增强)、细胞因子谱失调(特别是 IL-1、6、10 和 TNF-α)、淋巴细胞异常、免疫抑制反常(包括 HLA-DR 抑制和共抑制分子表达增加)以及肠道屏障功能障碍。也包括了包含干预措施的研究。已确定现有文献中的一些局限性;如果要在我们对这种疾病的理解方面取得进展,就需要对研究进行巩固和一致性处理。
AP,特别是更严重的疾病谱,其特征是多方面的免疫反应,可导致组织损伤,并导致相关的发病率和死亡率。如果要建立针对该疾病的治疗方法,就需要开展大量工作来加深我们对其免疫病理学的理解。